Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 12/14/2014
‘Among patients with chronic hepatitis B and hepatitis C, approximately 40% had no documented immunity or vaccination against hepatitis A or hepatitis B, according to recent study findings. “The presently reported US population-based estimates demonstrate that a substantial proportion of chronic viral hepatitis patients remain susceptible to vaccine-preventable hepatitis A and hepatitis B infections,” the researchers wrote in Clinical Infectious Diseases.’
‘The Patient-Centered Outcomes Research Institute, or PCORI, Board of Governors approved a PCORI Funding Announcement (PFA) that will provide up to $50 million for clinical effectiveness research studies focusing on effective ways to diagnose and treat hepatitis C virus infection, according to a company release.’
‘Gilead Sciences, Inc. (NASDAQ:GILD) stock has declined amid increasing competition in the hepatitis C market, especially the imminent arrival of AbbVie Inc’s (NYSE:ABBV) hepatitis C virus (HCV) regimen. The company’s stock price plunged 10.43% last month alone. Speculations abound that AbbVie would eat up Gilead’s market share and threaten the dominion of the biotech giant in the HCV space.’
‘A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal Science Translational Medicine, which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.’
‘A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C. The study, published today in PLOS ONE, used geospatial techniques to identify hotspots for deaths related to HIV/AIDS and hepatitis C. The findings show large disparities in death rates exist across race and ethnicity in Massachusetts.’
‘Philadelphia’s transit agency, SEPTA, has filed a class action lawsuit in federal court in Philadelphia against the drugmaker, Gilead, over the cost of its Hepatitis C drug known as Sovaldi. The three month regimen costs about $84,000 dollars and SEPTA says it has already spent more than $2 million on it.’